Biohaven's Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly's Emgality, According to Spherix Patient-Level Data
Retrieved on:
Thursday, September 23, 2021
Eli Lilly and Company, Pressure, Eli Lilly, NASA RealWorld-InWorld Engineering Design Challenge, FDA, MIDAS, Patient, Physician, Gastroenterology, Teva, CGRP, Allergan, Neurology, Topiramate, Calcitonin gene-related peptide, PDUFA, Dermatology, Amgen, AbbVie, Nephrology, Migraine Disability Assessment Test, Pharmaceutical industry
In the third annual audit included in Spherix's RealWorld Dynamix: Preventive Treatment in Migraine (US) service, 221 neurologists and migraine specialists provided data on 1,013 patients.
Key Points:
- In the third annual audit included in Spherix's RealWorld Dynamix: Preventive Treatment in Migraine (US) service, 221 neurologists and migraine specialists provided data on 1,013 patients.
- In comparison, close to one-third of patients recently prescribed Emgality were diagnosed with chronic migraine.
- The leading efficacy-related factor was prolonged or increased duration of migraine attacks when prescribed Emgality and persistently high or worsening migraine severity when prescribed Nurtec ODT.
- Likely benefiting from broad use as an acute therapy, Nurtec ODT is currently being prescribed as an earlier-line preventive therapy compared to Emgality.